Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kane Biotech Inc V.KNE

Alternate Symbol(s):  KNBIF

Kane Biotech Inc. is a Canada-based biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (66 patents and patents pending, trade secrets and trademarks) and products developed by its own biofilm research expertise and acquired from research institutions. DispersinB, coactiv+, coactiv+, DermaKB, DermaKB Biofilm, and revive are trademarks of the Company. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. In Wound Care & Surgical applications, in addition to revyve Antimicrobial Wound Gel, it is developing follow-on products with three applications: coactiv+ Antimicrobial Surgical Hydrogel, coactiv+ Antimicrobial Wound Gel Spray, and coactiv+ Antimicrobial Wound Rinse. The Company's other biofilm disruption technology is DispersinB.


TSXV:KNE - Post by User

Comment by MirrorWorldManon Mar 10, 2021 11:34am
94 Views
Post# 32762833

RE:RE:RE:+Efficacy Results in STEM Pet Oral Care Clinical Trial

RE:RE:RE:+Efficacy Results in STEM Pet Oral Care Clinical TrialAll the wheels of this company are turning, the management group is solid with partners in place, products have an exclusive niche, attention is being received from  the US army, research grants in place, deals are transparent, large market, growing revenues, solid financials and a strategic plan in place. Investor awareness is low and desire for new retail stock owners to purchase stock is stymied by a minimal social media presence and awareness of potential here. Getting attention of new investors should receive the same priority as other business functions imho. Creating a dedicated, experienced, working group or team to develop awareness and compete against other BioTech for the investment dollar needs to be top line as well. The increased market cap willl open up tremendous opportunities and gain attention of institutional investors.   Most large funds will not touch any stock under a 1-5 dollars.  So attract new investors or reverse split to bring up share price. Hiring a market maker isn't enough when share demand is low and there is little awareness. The only other hopeful is a buyout from an existing partner. 
<< Previous
Bullboard Posts
Next >>